Table 2 Relationships between BRAF expression and clinicopathological characteristics
Risk factors | BRAF strongly positive (n = 87) | BRAF weakly positive (n = 18) | χ2 | P value |
|---|---|---|---|---|
Age | 0.561 | 0.454 | ||
< 60 | 26 (29.8%) | 7 (38.8%) | ||
≥ 60 | 61 (70.1%) | 11 (61.1%) | ||
Gender | 2.688 | 0.101 | ||
Male | 61 (70.1%) | 16 (88.8%) | ||
Female | 26 (29.8%) | 2 (11.1%) | ||
Pathological type | 6.25 | 0.100 | ||
Protuberant type | 0 | 1 (5.5%) | ||
Ulcerative type | 52 (59.7%) | 10 (55.5%) | ||
Medullary type | 29 (33.3%) | 7 (38.8%) | ||
Mushroom type | 6 (6.8%) | 0 | ||
T stage | 0.570 | 0.903 | ||
T1 | 5 (5.7%) | 1 (5.5%) | ||
T2 | 10 (11.4%) | 2 (11.4%) | ||
T3 | 70 (88.4%) | 14 (77.7%) | ||
T4 | 2 (2.2%) | 1 (5.5%) | ||
N stage | 4.809 | 0.186 | ||
N0 | 38 (43.7%) | 9 (50.0%) | ||
N1 | 24 (27.6%) | 8 (44.4%) | ||
N2 | 21 (24.1%) | 1 (5.6%) | ||
N3 | 4 (4.6%) | 0 | ||
AJCC clinical staging | 1.756 | 0.416 | ||
Stage I | 5 (5.7%) | 0 | ||
Stage II | 37 (42.5%) | 10 (55.5%) | ||
Stage III | 45 (51.7%) | 8 (44.4%) | ||
Pathological grading | 0.259 | 0.879 | ||
I | 24 (27.5%) | 5 (27.7%) | ||
II | 55 (63.2%) | 12 (66.6%) | ||
III | 8 (9.1%) | 1 (5.5%) | ||
Ki67 | 11.067 | 0.001 | ||
< 14% | 13 (14.9%) | 9 (50.0%) | ||
≥ 14% | 74 (84.1%) | 9 (50.0%) | ||
p53 expression | 1.726 | 0.189 | ||
Strongly | 59 (67.8%) | 15 (83.3%) | ||
Weakly | 28 (31.1%) | 3 (16.6%) |